NetraMark Continues Expansion Into Phase 3 Programs With Contract From Global Biopharmaceutical Company
TORONTO, Dec. 11, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in th
(Financial Post, 2025-12-11T13:32:31Z)